NCT07534280

Completed

Herbal Tea Extract for Management of Rhinosinusitis

Deraya University Source

Compare

Other study identifiers

Sponsor study identifier

3 April 2026

Study Type

interventional

Actual enrollment (reported)

30

Locations

1 country

Sites

2

Timeline

Study Start

November 20, 2025

Actual (reported)

Primary Completion

January 10, 2026

Actual (reported)

Study Completion

March 1, 2026

Actual (reported)

Brief Summary

The objective of this phase I controlled clinical trial is to determine the safety and efficacy of Berry leaves \& Mango leaves mixture in symptomatic treatments on disease-related quality of life in adults with clinically diagnosed acute rhinosinusitis. Ten adult subjects, 18 to 70 years old, who meet the recommended criteria for acute rhinosinusitis, will be enrolled from Minia university ENT outpatient Clinic. Subjects will be advised to add Berry leaves \& Mango leaves herbal tea mixture and followed for one month with their routine therapy (an oral decongestant, a nasal saline spray, and an antitussive agent except analgesic). Subject outcomes will be assessed by telephone interview at 0, 3, 7, 10, and 28 days. The Quality-of-life outcomes are measured on Day 3, 10 and 28 with SNOT-16, a validated evaluative instrument.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 30 participants
Study completion date: March 1, 2026
Actual (reported)
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 20, 2025
Actual (reported)
Primary Completion
January 10, 2026
Actual (reported)
Study Completion
March 1, 2026
Actual (reported)
First Submitted
April 9, 2026
Actual (reported)
First Posted
April 16, 2026
Actual (reported)

Last Updated: April 16, 2026
Status Verified: April 2026
Last Update Submitted: April 15, 2026

Conditions

Rhino Sinusitis

Keywords

rhinosinusitisMango leafsteroidsSNOT-16

Outcome Measures

Primary Outcomes (1)

Reduction of SNOT 16 score after treatment
14 days

Study Arms (3)

herbal tea group

EXPERIMENTAL

Herbal tea 3 mgs three times a day plus oral antibiotic

Dietary Supplement: mango leaves extractDrug: amoxicillin clavulanates

Routine therapy

ACTIVE COMPARATOR

Steroid plus oral antibiotics in their normal doses

Drug: local steroidsDrug: amoxicillin clavulanates

Nasal irrigation Plus antibiotic

PLACEBO COMPARATOR

Interventions

mango leaves extractDietary supplement

herbal tea 3 times/day

herbal tea group

local steroidsDrug

local steroids once daily

Routine therapy

Eligibility Criteria

Age18 Years - 50 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

The subject must have symptoms of acute bacterial rhinosinusitis.
The subject should be able to be self-assessed as moderate, severe, or very severe.

Sponsors & Collaborators

Deraya University
Otherlead

Study Sites (2)

Soad A. Mohamad

Minya, Minya Governorate, 05673, Egypt

Deraya university

Minya, 05673, Egypt

MeSH Terms

Conditions

Rhinosinusitis

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

RhinitisRespiratory Tract InfectionsInfectionsSinusitisParanasal Sinus DiseasesNose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine Compounds

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: associate professor

Study Record Dates

First Submitted

April 9, 2026

First Posted

April 16, 2026

Study Start

November 20, 2025

Actual (reported)

NCT02097576

Manuka Honey Nasal Rinse Study

Not ApplicableWithdrawn

NCT00948519

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

Not ApplicableUnknown

NCT01680705

Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery

Not ApplicableCompleted

NCT00986830

Healthcare Utilization and Outcomes of FinESS Treatment in the Office

Not ApplicableCompleted

NCT03068728

Analysis of Hemostatic Agents Compared to Physiologic Hemostasis

Not ApplicableCompleted

NCT06866145

Dexmedetomidine Infusion in Either Total Intravenous Anesthesia or Inhalational Anesthesia to Improve Surgical Field Visibility in Endoscopic Sinus Surgery

Phase 4Completed

Nasal irrigation daily Plus oral antibiotics

Other: nasal salineDrug: amoxicillin clavulanates

nasal salineOther

nasal irrigation on need

Nasal irrigation Plus antibiotic

amoxicillin clavulanatesDrug

500 mg 3 times a day

Nasal irrigation Plus antibioticRoutine therapyherbal tea group

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

The subject must have access to a phone.

The subject must accept sharing and sign consent.

The subject should follow instructions carefully and not miss times of assessment

You may not qualify if:

The subject has an allergy to: Flavonoids, phenolic acids, anthocyanins, carotenoids.
The subject has complications of sinusitis (facial edema, cellulitis, or orbital, meningeal or cerebral signs).
The subject is pregnancy.
The subject has a comorbidity that may impair their immune response (such as immunodeficiency disease, uncontrolled cancer, or chemotherapy or radiation treatment).
The subject has cystic fibrosis

Contact the study team to confirm eligibility.

Inorganic Chemicals

Sodium Compounds

Primary Completion

January 10, 2026

Actual (reported)

Study Completion

March 1, 2026

Actual (reported)

Last Updated

April 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07534280
Data provider: ClinicalTrials.gov
Source updated: 2026-04-16
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:38 UTC

Locations

EG(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

herbal tea group

Routine therapy

Nasal irrigation Plus antibiotic

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations